Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NextCure ( (NXTC) ) has provided an update.
NextCure is set to engage with the investment community on November 8, 2024, focusing on their innovative therapeutic developments. Their ADC candidate, LNCB74, targets B7-H4 in women’s cancers and showcases promising preclinical results with enhanced safety and efficacy due to a unique glucuronidase linker. The company anticipates filing an IND by the end of 2024, with clinical trials poised to further evaluate its potential against breast, ovarian, and endometrial cancers.
Find detailed analytics on NXTC stock on TipRanks’ Stock Analysis page.